source
- Novartis inks second molecular glue partnership with Orionis, $40M upfrontNovartis has entered a second agreement with Orionis Biosciences focused on molecular glue technology. The deal includes an upfront payment of $40 million. The agreement also provides for mileston…
- SonoThera secures $125 million to advance ultrasound-based gene therapy for Duchenne and polycystic kidney diseaseSonoThera announced it has raised $125 million in financing to move its ultrasound-based non-viral gene therapy platform toward clinical testing. The funding will support the company’s two lead pr…